BioRunUp Review

Source: http://biorunupreview.com/ A lot of people buy stocks for downright STUPID reasons rumors, false hope and because a stock has a good story. And theres a way for you to profit as long as investors buy stocks for stupid reasons. Mark Messier track record is proof of that: Over the last two and a half years, hes taken his meager savings of $7,480 and turned it into $289,635. How? By playing the smart side of one sectors persistent stupidity. And now, Mark has released a free video revealing how you can do it, too. Nothing for sale just some ideas you can use to pad your profits in the months ahead. Reckless, gullible and greedy investors will always be with us. And they routinely transfer their wealth to investors who play it smart, safe and careful. You might as well be one of them. Utter B.S. That was my first reaction when Mark Messier a former crime analyst with no investment background claimed to have turned his life savings of $7,480 and into $289,635 in less than three years. But, at the urging of a mutual friend, I reluctantly agreed to take a closer look. And I was shocked to discover that hes actually the real deal. His broker statements prove it. It turns out that through sheer dumb luck, this guy discovered how he could make big profits by taking advantage of the reckless and greedy mistakes made by most investors. Better yet, those reckless investors take all the risk, while he reaps the reward! Best of all, Mark has released a free video revealing how you can do it, too. Click here to check it out I just heard from Mark Messier, the biotech trader I told you about who turned $7,480 into $289,635 over just the last 2 years. He tells me hes giving away 3 FREE memberships to his new biotech trading program. When you consider what Mark has accomplished, I think youll find it worth your while to try to win one of those memberships. It will only take a few minutes of your time.

Youll find all the details in the new Cold-Blooded Investors video that Mark just released. It reveals his powerful formula for investing in biotech stocks, a formula that lets you line your pockets by taking profitable advantage of the multitude of reckless and greedy investors in this sector. By the way, theres nothing for sale. Its just terrific content you can use to start making money in biotechs right away. Watch Marks new video and enter the contest here! One last thing: Mark has a valuable download for you. Its an Excel spreadsheet you can use immediately to begin pinpointing profitable biotechs using Marks formula. Better yet, hes giving you a head start by listing every biotech hes looking at now, along with a variety of details about each one. Bottom line: If you want to give your portfolio a nice profit boost and have a shot at winning one of the free memberships, you need to watch this video today. I just had a look at Marks track record, and its astounding. It boasts winners like Fibrocell Science, up 242.3% in just 4 months enough to turn $2,500 into $8,557 Neoprobe Corporation, up 204.44% in just over 6 months enough to turn $2,500 into $7,611 or Depomed, up 171.75% in 6 months enough to turn $2,500 into $6,793. No wonder he turned $7,480 into $289,635! This guy knows how to pick em. Biotech Breakout Trader also known as BioRunUp was created in 2010 by Mark Messier, below is his story When I graduated high school I began working at Bank of America (BAC) while attending college. Seeing the price of BAC fall to $3 a share, I had a sense that this was a good time to buy. At the time I didnt have much of a trading account, but I managed to buy about 1500 shares. The recent upturn of the financial industry increased my portfolio and gave me the confidence and opportunity to branch out in other areas of the market. That is when I discovered biotechs. CTIC will always hold a special place in my heart, it was the first biotech that I ever traded. I bought a few thousand shares in the $.30 range, and watched it grow to well over $1. Next was HEB. Although now former HEBbers view that stock as a nightmare, I watch my original buy of $.96 climb to $4.54. This ignited my interest in biotech stocks. The more research I performed the more excited I got. There seems to be a semi-predictable pattern with FDA Catalyst stocks. Simply put- Buy early, let the anticipation drive the price up, then sell. However, it is not that simple. In this confusing sector there was no reliable source of legitimate FDA catalysts. From this void BioRunUp was created.

I have always had a simplistic view of money. It is not what makes you happy. This viewpoint is very contrary to the majority on Wall Street to whom money is everything. These feelings only grew once we had our first child in 2007. We spent the first 7 years of our marriage traveling as much as possible. The tropical climate has always appealed to us, and we made a few trips down to Costa Rica, before purchasing a piece of land on the Pacific coast in 2007. I look forward to living and trading in a relaxed tropical climate and spending more time with my family. This is something life in cubicle-ville can never offer. Successful Trading In 2009 my biotech portfolio increased by 273%, and another 216% in 2010. Lets Ride the Waves of Biotech Together Riding the ups and downs of biotechs can be a mix of skill and timing. It does not look like this sector will be going anywhere any time soon. As long as there is sickness, there will be a biotech market. With a healthy combination of run-ups, free shares, shorting, and options I feel there is a huge potential in these plays. That being said, lets go ride the waves. For those not familiar with the Run-Up method, here is the concept: Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. Only at this point are some drugs assigned a date, at which approval or denial is to be announced. This decision date is known at least 6 months in advance. The Run-Up method involves locating and buying shares of these companies well before their decision date, riding the share price up, and selling BEFORE the FDA announces their decision. The concept can also be applied to clinical trials with data releases. The goal is simple: Minimize risk while maximizing consistent profits. This system has a proven track record of success. In 2009 my biotech portfolio gained 273%, in 2010 216%, and 155% 2011 YTD. The concept seems simple- buy early, hold, and sell before the catalyst. However, it can be quite complicated. What is the key to successfully trading biotech catalyst events? Research, Research, and more Research By the time you hear about one of these stocks in the news it is too late. The best profits are made by getting in before the masses. This is what BioRunUp.com subscription service provides for you. We are constantly researching and using every resource available to find the next catalyst event. Some of our sources include:

- Paid Subscription Services SEC Filings News Feed Searches Phase III Trial Results Forums & Bulletin Boards Company Websites Not every FDA or Clinical catalyst will result in a run-up. When taking into account what stocks to discuss we take into account many factors, including (but not limited to) the following: Company Market Cap Drug Type (Potential Market) Cash on Hand (Dilution) Perception of Approval Odds New NDA or ReSubmission Is an FDA Panel Scheduled Partnerships Management Reputation As you can see, this is not a simple process. Many hours of careful research and analysis is required for each and every stock. The majority of the stocks we research do not meet our strict criteria and are not published.